Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | EDNRB | P24530 | 3/20 | 0.45 |
| ▸ | EDNRA | P25101 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810186 | 0.92 | SERPINE1 (0.54) | SERPINE1KMT2AMEN1ALDH1A1USP2 | |
| SCHEMBL2810361 | 0.90 | SERPINE1 (0.51) | SERPINE1KMT2AMEN1ALDH1A1USP2 | |
| SCHEMBL14270697 | 0.90 | KMT2A (0.53) | SERPINE1KMT2AMEN1ALDH1A1USP2 | |
| SCHEMBL2807928 | 0.89 | KDM4E (0.44) | SERPINE1KMT2AMEN1ALDH1A1USP2 | |
| SCHEMBL2809001 | 0.88 | SERPINE1 (0.50) | SERPINE1KMT2AMEN1ALDH1A1USP2 | |
| SCHEMBL2806751 | 0.87 | SERPINE1 (0.49) | SERPINE1KMT2AMEN1ALDH1A1USP2 | |
| SCHEMBL4397413 | 0.87 | SERPINE1 (0.52) | SERPINE1KMT2AMEN1ALDH1A1USP2 | |
| SCHEMBL2813528 | 0.86 | SERPINE1 (0.50) | SERPINE1KMT2AMEN1ALDH1A1USP2 | |
| SCHEMBL2810203 | 0.85 | SERPINE1 (0.62) | SERPINE1EDNRBEDNRAPPARGFOLH1 | |
| SCHEMBL2807069 | 0.85 | SERPINE1 (0.51) | SERPINE1KMT2AMEN1ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | claimed |
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2081894-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SmithKline Beecham Corporation (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008028118-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SMITHKLINE BEECHAM CORPORAITON (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008028118-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SMITHKLINE BEECHAM CORPORAITON (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | PPARD, PPARA, PPARG | SERPINE1 4215/4885KMT2A 2100/4885MEN1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.